Yulia Y. Maxuitenko

Oral PDE10 inhibitor ADT-030 curbed KRAS-mutant pancreatic cancer growth and metastasis in mouse models, stayed active in KRAS-inhibitor-resistant cells, and shifted tumor immune profiles.

This study shows that PDE10A inhibition with ADT-030 suppresses tumor growth by disrupting MAPK signaling and enhancing antitumor immunity through immune cell modulation.

ADT-1004, a pan-RAS inhibitor, shows strong antitumor activity in pancreatic ductal adenocarcinoma models with high selectivity and tolerable dosing.

This study evaluates the potency and selectivity of the pan-RAS inhibitor ADT-007 in 3D bioprinted organoid tumor models of KRAS-mutant and RAS wild-type colorectal cancer.